Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
A recent pullback in shares of Eli Lilly, one of the leaders in GLP-1 medications, presented an opportunity to initiate a position. We believe the...
— Delaware Management Company (now part of Nomura Asset Management)
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Eli Lilly & Co.
Eli Lilly and Company ($LLY) is a global pharmaceutical leader specializing in treatments for diabetes, obesity, oncology, and immunology, representing the Fund's largest portfolio holding at 14.3% of net assets. The manager maintains...
Eli Lilly is a premier multinational pharmaceutical company engaged in the research, development, and commercialization of therapeutics, currently dominating the global market for diabetes and obesity treatments. The manager is...
The company remains a premier growth compounder in the highly underserved global diabetes and obesity therapeutic markets. While the market...
More institutional theses from Nomura Large Cap Growth Fund
Microsoft Corp. ($MSFT) represents 8.93% of the portfolio and provides enterprise software, cloud infrastructure via Azure, and productivity platforms. The investment manager...
Meta Platforms Inc. ($META) operates global social networking applications and digital advertising networks, including Facebook, Instagram, and WhatsApp. The manager maintained...
Vulcan Materials Co. ($VMC) is a leading domestic producer of construction aggregates, including crushed stone, sand, and gravel, alongside asphalt and ready-mixed concrete. The manager remains...